Doxofylline has been used as a phosphodiesterase (PDE) inhibitor to study its protective effects on lipopolysaccharides (LPS)-induced inflammatory response in human pulmonary bronchial epithelial cells. It has also been used to study its interaction with bovine serum albumin (BSA).
Biochem/physiol Actions
Doxofylline (also known as doxophylline) has antitussive and bronchodilator effects. Doxofylline is used clinically in the treatment of asthma. Doxofylline has similar efficacy to theophylline, but unlike theophylline or other xanthines has little affinity for adenosine receptors and does not produce stimulant effects and has significantly fewer side effects.
Doxofylline acts and as a non-selective phosphodiesterase (PDE) inhibitor and exhibits anti-inflammatory activity. It has the potential to treat chronic obstructive pulmonary disease (COPD).
General description
Doxofylline is a novel xanthine derivative comprising of dioxolone group.